IL-4 His-Tagged Protein: Unraveling the IL-4/IL-4Rα Axis in Tumor Immune Evasion

Concept: IL-4 – A Key Cytokine Linking Immune Remodeling and Tumor Immune Evasion

Interleukin-4 (IL-4) is a pleiotropic cytokine traditionally recognized for its central role in type 2 immune responses, allergic reactions, and B cell activation. However, emerging research has uncovered a critical and previously underappreciated function of IL-4 in tumor biology: its role as a driver of immune remodeling that facilitates tumor immune evasion. During tumorigenesis and progression, the body’s systemic and local immune landscapes undergo profound alterations—characterized by the mobilization of immunosuppressive myeloid cells, expansion of regulatory immune subsets (e.g., Tregs, Bregs), and impairment of effector T cell and dendritic cell function. At the heart of this immune dysregulation lies the IL-4/IL-4 receptor α (IL-4Rα) signaling axis, which orchestrates the generation of immunosuppressive myeloid cells from early hematopoietic progenitors, creating a tumor-permissive microenvironment that suppresses antitumor immunity.

IL-4 exerts its biological effects by binding to the IL-4Rα subunit, which forms a heterodimeric receptor complex with either the common γ-chain (for classic signaling) or IL-13Rα1 (for cross-signaling with IL-13). In the context of tumor immune evasion, IL-4 signaling specifically targets granulocyte-monocyte progenitors (GMPs) in the bone marrow, modulating their transcriptional programs to drive differentiation into immunosuppressive monocytes, macrophages, and other myeloid lineages. These cells subsequently infiltrate the tumor microenvironment, where they suppress effector T cell activity, promote angiogenesis, and support tumor cell proliferation and metastasis—making the IL-4/IL-4Rα axis a critical therapeutic target for reversing immune suppression and enhancing antitumor immunity.

Research Frontiers of IL-4 in Tumor Immune Evasion

The field of IL-4 research in tumor immunology is advancing rapidly, with cutting-edge investigations focusing on unraveling the precise mechanisms by which IL-4 drives immune remodeling and exploring novel therapeutic strategies targeting this axis. A core research frontier is identifying the cellular sources and regulatory triggers of IL-4 in the tumor context. Recent studies have pinpointed bone marrow-resident basophils as the primary producers of IL-4 that activates GMPs, with soluble factors from the tumor microenvironment likely acting as long-range signals to stimulate IL-4 secretion. This discovery links systemic immune alterations to local tumor immunosuppression, highlighting a previously unrecognized cross-talk between the tumor and bone marrow.

Another key research direction is defining the lineage-specific effects of IL-4 signaling. Genetic studies have demonstrated that deletion of IL-4Rα in early GMPs—rather than mature myeloid cells—effectively inhibits tumor growth and reduces immunosuppressive myeloid cell accumulation, underscoring the critical role of early hematopoietic progenitors as targets of IL-4. This finding has guided the development of targeted therapies that block IL-4/IL-4Rα signaling at the progenitor level, avoiding off-target effects on mature immune cells. Additionally, research is exploring the synergistic potential of combining IL-4/IL-4Rα inhibitors with immune checkpoint blockade (e.g., anti-PD-1/PD-L1) to overcome myeloid-mediated immune resistance, a major limitation of current immunotherapies.

Accurate detection and functional characterization of IL-4 are fundamental to these advances. The IL-4 His-tagged recombinant protein serves as an indispensable tool for studying IL-4 signaling, validating receptor-ligand interactions, and screening potential inhibitors—enabling researchers to dissect the complex role of IL-4 in tumor immune evasion.

Research Significance of IL-4 in Tumor Immune Evasion

Unraveling the role of IL-4 in tumor immune evasion holds profound scientific, clinical, and translational significance for oncology, immunology, and precision medicine.

In basic research, IL-4 studies provide critical insights into the molecular mechanisms linking systemic immune remodeling to local tumor immunosuppression. By elucidating how IL-4 signaling modulates hematopoietic progenitor cell fate, researchers gain a deeper understanding of immune cell development and immune regulation in the context of cancer—knowledge that challenges traditional views of IL-4 as a purely type 2 immune cytokine and expands our understanding of tumor-immune interactions. This research also sheds light on the broader role of myeloid cells in immune evasion, informing the development of strategies to target other myeloid-driven pathways.

Translationally, the IL-4/IL-4Rα axis represents a promising therapeutic target for improving immunotherapy outcomes. Current immune checkpoint inhibitors benefit only a subset of patients, often due to the presence of immunosuppressive myeloid cells in the tumor microenvironment. Blocking IL-4/IL-4Rα signaling can reverse this myeloid-mediated suppression, reprogram the tumor microenvironment, and enhance the efficacy of existing immunotherapies. Additionally, IL-4-targeted therapies may offer new options for patients with tumors refractory to conventional treatments, addressing an unmet clinical need.

Clinically, IL-4 and IL-4Rα expression profiles hold potential as predictive biomarkers for patient stratification. By measuring IL-4 levels in the bone marrow, peripheral blood, or tumor microenvironment, clinicians can identify patients with active IL-4/IL-4Rα signaling who may benefit from targeted therapies or combination immunotherapies. This personalized approach has the potential to optimize treatment outcomes and reduce unnecessary toxicity.

Mechanisms, Research Methods and Product Applications

Core Mechanisms of IL-4-Mediated Tumor Immune Evasion

IL-4 drives tumor immune evasion through a well-orchestrated, multi-step mechanism centered on the regulation of myeloid cell development and function:

1. Tumor-induced IL-4 production: Soluble factors secreted by the tumor microenvironment travel via the circulation to the bone marrow, stimulating basophils and other type 2 immune cells to produce IL-4.
2. GMP targeting and reprogramming: IL-4 binds to IL-4Rα expressed on GMPs, activating downstream signaling pathways (e.g., JAK-STAT6) that alter the transcriptional profile of progenitors. This reprogramming diverts GMP differentiation away from immunostimulatory myeloid lineages and toward immunosuppressive monocytes, macrophages, and myeloid-derived suppressor cells (MDSCs).
3. Immunosuppressive myeloid cell infiltration: The newly generated immunosuppressive myeloid cells enter the circulation and infiltrate the tumor microenvironment and draining lymph nodes.
4. Tumor microenvironment suppression: Within the tumor, these myeloid cells suppress antitumor immunity by inhibiting effector T cell activation and proliferation, promoting Treg expansion, and producing anti-inflammatory cytokines (e.g., IL-10, TGF-β). They also support tumor growth by promoting angiogenesis and tissue remodeling.

Key Research Methods for IL-4 and Tumor Immune Evasion Studies

Investigating IL-4’s role in tumor immune evasion requires specialized tools and techniques to study signaling pathways, myeloid cell differentiation, and immune function. Core research methods include:

• Functional characterization of IL-4 signaling: In vitro culture of GMPs or hematopoietic progenitors with recombinant IL-4 to assess differentiation into immunosuppressive myeloid cells, using flow cytometry to analyze surface marker expression (e.g., CD11b, Gr-1, CD206).
• Genetic and pharmacological inhibition studies: Use of IL-4Rα knockout mice or small-molecule inhibitors to validate the role of IL-4/IL-4Rα signaling in tumor growth and myeloid cell generation.
• Quantification of IL-4 and receptor expression: ELISA, qPCR, or immunohistochemistry to measure IL-4 protein levels in bone marrow, serum, or tumor samples, and flow cytometry to assess IL-4Rα expression on GMPs and myeloid cells.
• Tumor models and efficacy studies: In vivo tumor models (e.g., lung cancer, melanoma) to evaluate the antitumor effects of targeting IL-4/IL-4Rα, including measurements of tumor burden, myeloid cell infiltration, and effector T cell function.
• Drug screening: High-throughput screening of potential IL-4/IL-4Rα inhibitors using recombinant IL-4 and IL-4Rα-expressing reporter cells or GMPs.

ANT BIO PTE. LTD.’s IL-4 His-Tagged Recombinant Protein: Empowering Tumor Immunology Research

ANT BIO PTE. LTD. addresses the critical need for high-quality IL-4 research tools through its UA sub-brand (specializing in high-purity recombinant proteins), offering the Human IL-4 (His-Tag) Recombinant Protein (Catalog No.: S0A4021). Expressed in the HEK293 mammalian cell system with a C-terminal His-tag, this protein closely mimics the amino acid sequence, dimeric structure, and biological activity of native human IL-4, making it an indispensable tool for studying IL-4-mediated tumor immune evasion, type 2 immunity, and drug development.

Core Advantages of ANT BIO PTE. LTD.’s Human IL-4 (His-Tag) Recombinant Protein (S0A4021)

Key Application Scenarios for S0A4021 Human IL-4 (His-Tag) Recombinant Protein

1. Tumor Immune Evasion Mechanism Studies: Induce differentiation of GMPs or hematopoietic progenitors into immunosuppressive myeloid cells to study IL-4-mediated transcriptional reprogramming and lineage commitment.
2. Myeloid Cell Function Assays: Evaluate the effects of IL-4 on macrophage polarization (M1 vs. M2) and the functional properties of immunosuppressive myeloid cells (e.g., T cell suppression, cytokine secretion).
3. Drug Screening and Inhibitor Evaluation: Serve as a critical tool for high-throughput screening of IL-4/IL-4Rα inhibitors (small molecules, monoclonal antibodies); validate inhibitor efficacy by assessing blockade of IL-4-mediated signaling or myeloid cell differentiation.
4. Type 2 Immunity and Allergy Research: Study IL-4’s role in Th2 cell differentiation, B cell activation, and IgE class switching—providing insights into the overlap between allergic responses and tumor immune evasion.
5. Receptor-Ligand Interaction Studies: Characterize the binding affinity and kinetics of IL-4 with IL-4Rα using surface plasmon resonance (SPR) or bio-layer interferometry (BLI), supporting structure-based drug design.
6. Cell Culture and Differentiation: Support the growth and differentiation of IL-4-dependent cell lines (e.g., TF-1 cells, B cell lymphomas) for in vitro functional assays.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.